Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 5/2020

01-04-2020 | Sarcoma | AdisInsight Report

Tazemetostat: First Approval

Author: Sheridan M. Hoy

Published in: Drugs | Issue 5/2020

Login to get access

Abstract

Tazemetostat (Tazverik™), a first-in-class, small molecule enhancer of zeste homolog 2 (EZH2) inhibitor, received accelerated approval in January 2020 in the USA for the treatment of adults and adolescents aged ≥ 16 years with locally advanced or metastatic epithelioid sarcoma not eligible for complete resection. Developed by Epizyme, in collaboration with Eisai, it is the first therapy to be approved specifically for the treatment of epithelioid sarcoma in the USA. The recommended dosage regimen is 800 mg twice daily, administered orally with or without food, until disease progression or unacceptable toxicity. Tazemetostat is also undergoing clinical development in various countries worldwide for use in several other tumour types, including diffuse large B-cell lymphoma and mesothelioma, with the US FDA accepting a New Drug Application and granting priority review for its use in the treatment of follicular lymphoma. This article summarizes the milestones in the development of tazemetostat leading to this first approval for the treatment of adults and adolescents aged ≥ 16 years with locally advanced or metastatic epithelioid sarcoma not eligible for complete resection.
Literature
1.
Lue JK, Amengual JE. Emerging EZH2 inhibitors and their application in lymphoma. Curr Hematol Malig Rep. 2018;13(5):369–82.CrossRef
2.
3.
Gulati N, Beguelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59(7):1574–85.CrossRef
4.
Epizyme. Epizyme announces exercise of $50 million option with Royalty Pharma and highlights key 2020 initiatives to build long-term value [media release]. http://​www.​epizyme.​com. Accessed 6 Jan 2020.
5.
6.
US FDA. FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer. 2020. http://​www.​fda.​gov/​. Accessed 29 Jan 2020.
7.
8.
9.
Epizyme. Epizyme announces FDA acceptance of New Drug Application for filing with Priority Review for TAZVERIK™ (tazemetostat) for the treatment of follicular lymphoma [media release]. 14 Feb 2020. http://​www.​epizyme.​com/​.
10.
11.
12.
13.
14.
15.
Epizyme. Epizyme enters worldwide strategic partnership with Eisai for cancer therapeutics targeting EZH2 epigenetic enzyme [media release]. 11 Mar 2011. http://​www.​epizyme.​com.
16.
Epizyme. Epizyme initiates collaboration on combination trial of tazemetostat and Tecentriq(TM) (atezolizumab) for treatment of non-Hodgkin lymphoma [media release]. 22 Jun 2016. http://​www.​epizyme.​com.
17.
18.
19.
Epizyme. Epizyme establishes agreements for up to $270 Million in funding to support tazemetostat commercialization and pipeline advancement [media release]. 5 Nov 2019. http://​www.​epizyme.​com.
20.
Comet I, Riising EM, Leblanc B, et al. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer. 2016;16(12):803–10.CrossRef
21.
Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011;35(10):e47–63.CrossRef
22.
Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110(19):7922–7.CrossRef
23.
Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13(4):842–54.CrossRef
24.
Chan-Penebre E, Armstrong K, Drew A, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models. Mol Cancer Ther. 2017;16(5):850–60.CrossRef
25.
Motwani V, Brach D, Pantano C, et al. Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion [abstract no. B011]. Mol Cancer Ther. 2019;18(12 Suppl).
26.
Hood TL, Cosmopoulos K, Drew A, et al. Opportunity for therapeutic expansion in mantle cell lymphoma: tazemetostat combination synergy status in preclinical MCL models [abstract no. 808/18]. In: 109th Annual Meeting of the American Association for Cancer Research. 2018.
27.
28.
Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649–59.CrossRef
29.
30.
Stacchiotti S, Blay JY, Jones RL, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950) [abstract no. 1611PD]. Ann Oncol. 2018;29(Suppl 8):viii580.CrossRef
31.
Stacchiotti S, Schoffski P, Jones R, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950) [abstract no 11003]. J Clin Oncol. 2019;37(15 Suppl):11003.CrossRef
32.
Jones RL, Blay JY, Agulnik M, et al. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950) [abstract no. 1612PD]. Ann Oncol. 2018;29(Suppl 8):viii580–1.CrossRef
33.
Schoffski P, Agulnik M, Stacchiotti S, et al. Phase 2 multicenter study of the EZH2 inhibitor tzemetostat in adults with synovial sarcoma (NCT02601950) [abstract no. 11057]. J Clin Oncol. 2017;35(15 Suppl):11057.CrossRef
34.
Ribrag V, Morschhauser F, McKay P, et al. Interim results from an ongoing phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) [abstract no. 4196]. Blood. 2018;132(Suppl 1).
35.
Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma [abstract no. 123]. Blood. 2019;134(Suppl 1).
36.
Zauderer MG, Szlosarek P, Le Moulec S, et al. Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation [abstract no. 8515]. J Clin Oncol. 2018;36(15 Suppl):8515.CrossRef
37.
Palomba ML, Cartron G, Popplewell L, et al. Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: primary analysis of a phase 1b study [abstract no. 493]. Hematol Oncol. 2019;37(Suppl 2):517–9.CrossRef
38.
39.
Epizyme. Epizyme announces FDA filing acceptance of New Drug Application and Priority Review for tazemetostat for the treatment of epithelioid sarcoma [media release]. http://​www.​epizyme.​com. Accessed 26 Jul 2019.
Metadata
Title
Tazemetostat: First Approval
Author
Sheridan M. Hoy
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Drugs / Issue 5/2020
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-020-01288-x

Other articles of this Issue 5/2020

Drugs 5/2020 Go to the issue

Leading Article

Mechanisms of Resistance to PD-1 Checkpoint Blockade

Adis Drug Evaluation

Cenegermin: A Review in Neurotrophic Keratitis

Original Research Article

Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study

AdisInsight Report

Trastuzumab Deruxtecan: First Approval

Correction

Correction to: Ubrogepant: First Approval

Leading Article

Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments